Skip to main content

Articles

Page 13 of 17

  1. To evaluate the association between angiotensin I-converting enzyme insertion/deletion (ACE I/D) gene polymorphism and retinal vein occlusion (RVO). A total of 80 patients with retinal vein occlusion who was a...

    Authors: Işıl Kutluturk, Ali Karagöz, Tahir Bezgin, Vecih Oduncu, Ali Elveran, Cem Doğan, Ahmet Elbay, Cevat Kirma and Yusuf Özertürk
    Citation: Thrombosis Journal 2014 12:17
  2. Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism, poses a substantial clinical risk, and the incidence of these thrombotic-related diseases remains high. Anticoagulati...

    Authors: Walter Ageno, Lorenzo G Mantovani, Sylvia Haas, Reinhold Kreutz, Verena Haupt, Jonas Schneider and Alexander GG Turpie
    Citation: Thrombosis Journal 2014 12:16
  3. Venous thromboembolic disease (VTE) is associated with high morbi-mortality. Adherence rate to the recommendations of antithrombotic prophylaxis guidelines (ATPG) is suboptimal. The aim of this study was to de...

    Authors: Fernando Vazquez, Ricardo Watman, Aldo Tabares, Carina Gumpel, Enrique Baldessari, Alicia B Vilaseca, Federico J Capparelli and Esteban Lifschitz
    Citation: Thrombosis Journal 2014 12:15
  4. Atrial fibrillation (AF) patients frequently require anticoagulation with vitamin K antagonists (VKAs) to prevent thromboembolic events, but their use increases the risk of hemorrhage. We evaluated time spent ...

    Authors: Elizabeth S Mearns, C Michael White, Christine G Kohn, Jessica Hawthorne, Ju-Sung Song, Joy Meng, Jeff R Schein, Monika K Raut and Craig I Coleman
    Citation: Thrombosis Journal 2014 12:14
  5. Atrial fibrillation (AF) is a common cardiac arrhythmia, and leading cause of ischemic stroke. Despite proven effectiveness, warfarin remains an under-used treatment in atrial fibrillation patients. We sought ...

    Authors: Stuart G Nicholls, Jamie C Brehaut, Rubab G Arim, Kelly Carroll, Richard Perez, Kaveh G Shojania, Jeremy M Grimshaw and Roy M Poses
    Citation: Thrombosis Journal 2014 12:13
  6. Deep venous thrombosis (DVT), which is often associated with pulmonary embolism (PE), is a serious complication after total knee arthroplasty (TKA). In the present study, we examined the overall thrombotic and...

    Authors: Yukinori Tamura, Shigeshi Mori, Shigeki Asada, Naoyuki Kawao, Shigeru Ueshima, Hiroshi Kaji, Junichiro Yamamoto, Masao Akagi and Osamu Matsuo
    Citation: Thrombosis Journal 2014 12:11
  7. Platelet inhibitors are commonly used to reduce the risk of atherothrombotic events. The aim of this study was to determine the impact of platelet inhibitors, specifically clopidogrel and aspirin, on clot kine...

    Authors: Joseph F Dwyer, Jill A McCoy, Ziping Yang, Michael Husser, Heinz Redl, Mary Ann Murphy, Martin Wolfsegger, James P DiOrio, Andreas Goppelt and Shane Donovan
    Citation: Thrombosis Journal 2014 12:10
  8. Venous thromboembolism (VTE) prophylaxis is underutilized for hospitalized patients. The primary objective of this study was to assess the impact of a continuing medical education (CME) program on thromboproph...

    Authors: Fahad Al-Hameed, Hasan M Al-Dorzi and Essam Aboelnazer
    Citation: Thrombosis Journal 2014 12:9
  9. New oral anticoagulant (NOAC) drugs are known to influence the results of some routine hemostasis tests. Further data are needed to enable routine assessment of the effects of NOAC on clotting parameters in so...

    Authors: Raul Altman and Claudio Daniel Gonzalez
    Citation: Thrombosis Journal 2014 12:7
  10. Thromboelastography® (TEG) utilizes kaolin, an intrinsic pathway activator, to assess clotting function. Recent published studies suggest that TEG results are commonly normal in patients receiving warfarin, de...

    Authors: C Michael Dunham, Charlene Rabel, Barbara M Hileman, Jason Schiraldi, Elisha A Chance, Mark T Shima, Alddo A Molinar and David A Hoffman
    Citation: Thrombosis Journal 2014 12:4
  11. The Editors of Thrombosis Journal would like to thank all our reviewers who have contributed to the journal in Volume 11 (2013).

    Authors: Yukio Ozaki and Hugo ten Cate
    Citation: Thrombosis Journal 2014 12:2
  12. Paxillin is a LIM domain protein localized at integrin-mediated focal adhesions. Although paxillin is thought to modulate the functions of integrins, little is known about the contribution of paxillin to signa...

    Authors: Asuka Sakata, Tsukasa Ohmori, Satoshi Nishimura, Hidenori Suzuki, Seiji Madoiwa, Jun Mimuro, Kazuomi Kario and Yoichi Sakata
    Citation: Thrombosis Journal 2014 12:1
  13. Atrial fibrillation (AF) is a common tachyarrhythmia in Australia, with a prevalence over 10% in older patients. AF is the leading preventable cause of ischaemic stroke, and strokes due to AF have a higher mor...

    Authors: Christopher Ward, Greg Conner, Geoffrey Donnan, Alexander Gallus and Simon McRae
    Citation: Thrombosis Journal 2013 11:27
  14. Left atrial appendage (LAA) thrombosis is an important cause of cardiogenic cerebral thromboembolism. Apixaban is a member of the class of novel oral anticoagulants (NOAC) and is superior to warfarin in preven...

    Authors: Tohru Kawakami, Hiroko Kobayakawa, Hiroyoshi Ohno, Nobukiyo Tanaka and Hiroki Ishihara
    Citation: Thrombosis Journal 2013 11:26
  15. The worldwide EINSTEIN DVT and EINSTEIN PE studies randomized 8282 patients with acute symptomatic deep-vein thrombosis (DVT) and/or pulmonary embolism (PE) and, for the first time in trials in this setting, i...

    Authors: Yuqi Wang, Chen Wang, Zhong Chen, Jiwei Zhang, Zhihong Liu, Bi Jin, Kejing Ying, Changwei Liu, Yuxia Shao, Zhicheng Jing, Isabelle Ling Meng, Martin H Prins, Ákos F Pap, Katharina Müller and Anthonie WA Lensing
    Citation: Thrombosis Journal 2013 11:25
  16. Lupus anticoagulant (LA) is known to inhibit thrombin generation although patients have an increased risk to develop thrombosis. We tried to determine whether thrombin generation is altered in plasma samples o...

    Authors: Klas Boeer, Leonid Cuznetov and Wolfgang Loesche
    Citation: Thrombosis Journal 2013 11:24
  17. Platelets were activated under the infection with H. pylori in human and mice. We investigated the role of VacA, an exotoxin released by H. pylori in this context. Acid-activated VacA, but not heated VacA, induce...

    Authors: Kaneo Satoh, Toshiya Hirayama, Katsuhiro Takano, Katsue Suzuki-Inoue, Tadashi Sato, Masato Ohta, Junko Nakagomi and Yukio Ozaki
    Citation: Thrombosis Journal 2013 11:23
  18. Plasma protein-C exerts anticoagulatory effects by inactivating factors V and VIII. Hereditary protein C deficiency is transmitted as an autosomal dominant disorder. Homozygous individuals usually develop purp...

    Authors: Syed Maqbool, Vishal Rastogi, Ashok Seth, Satbir Singh, Vijay Kumar and Arif Mustaqueem
    Citation: Thrombosis Journal 2013 11:19
  19. Standard treatment for venous thromboembolism (VTE) consists of a heparin combined with vitamin K antagonists. Direct oral anticoagulants have been investigated for acute and extended treatment of symptomatic ...

    Authors: Martin H Prins, Anthonie WA Lensing, Rupert Bauersachs, Bonno van Bellen, Henri Bounameaux, Timothy A Brighton, Alexander T Cohen, Bruce L Davidson, Hervé Decousus, Gary E Raskob, Scott D Berkowitz and Philip S Wells
    Citation: Thrombosis Journal 2013 11:21
  20. Anticoagulation with vitamin K antagonists such as warfarin has historically been used for the long term management of patients with thromboembolic disease. However, these agents have a slow onset of action wh...

    Authors: Faryal Tahir, Haris Riaz, Talha Riaz, Maaz B Badshah, Irbaz B Riaz, Ameer Hamza and Hafsa Mohiuddin
    Citation: Thrombosis Journal 2013 11:18
  21. Behcet’s disease is a chronic multi-system disorder of unknown etiology with protean manifestations. Venous thromboembolism is more common than arterial thrombosis, with deep vein thrombosis being the most fre...

    Authors: Hoda Abdel Badaee, Amr Edrees, Sherif Amin, Maher El Amir and Gaafar Ragab
    Citation: Thrombosis Journal 2013 11:17
  22. The incidence of venous thromboembolic disease (VTED) is estimated to be, on average, 1–2 cases per 1,000 individuals per year worldwide. There are few data concerning the incidence rate (IR) of VTED in the Ar...

    Authors: Fernando Javier Vázquez, María Lourdes Posadas-Martínez, Jimena Vicens, Fernán González Bernaldo de Quirós and Diego Hernán Giunta
    Citation: Thrombosis Journal 2013 11:16
  23. Atrial fibrillation (AF) is the most common form of heart arrhythmia and a leading cause of stroke and systemic embolism. Chronic anticoagulation is recommended for preventing those complications. Our study ai...

    Authors: Léon Nshimyumukiza, Julie Duplantie, Mathieu Gagnon, Xavier Douville, Diane Fournier, Carmen Lindsay, Marc Parent, Alain Milot, Yves Giguère, Christian Gagné, François Rousseau and Daniel Reinharz
    Citation: Thrombosis Journal 2013 11:14
  24. Direct oral anticoagulants that target a single coagulation factor have been developed as an alternative to standard therapies with heparin and/or vitamin K antagonists. The purpose of this study was to derive...

    Authors: Martin H Prins and Anthonie WA Lensing
    Citation: Thrombosis Journal 2013 11:13
  25. Microplate-based thrombin generation test (TGT) is widely used as clinical measure of global hemostatic potential and it becomes a useful tool for control of drug potency and quality by drug manufactures. Howe...

    Authors: Yideng Liang, Samuel A Woodle, Alexey M Shibeko, Timothy K Lee and Mikhail V Ovanesov
    Citation: Thrombosis Journal 2013 11:12
  26. Research into new anticoagulants for preventing and treating thromboembolic disorders has focused on targeting single enzymes in the coagulation cascade, particularly Factor Xa and thrombin, inhibition of whic...

    Authors: Meyer Michel Samama, Geneviève Contant, Theodore E Spiro, Elisabeth Perzborn, Lena Le Flem, Céline Guinet, Yves Gourmelin, Gabriele Rohde and Jean-Luc Martinoli
    Citation: Thrombosis Journal 2013 11:11
  27. Unlike traditional anticoagulants, the more recently developed agents rivaroxaban, dabigatran and apixaban target specific factors in the coagulation cascade to attenuate thrombosis. Rivaroxaban and apixaban d...

    Authors: Wolfgang Mueck, Stephan Schwers and Jan Stampfuss
    Citation: Thrombosis Journal 2013 11:10
  28. While the assessment of analytical precision within medical laboratories has received much attention in scientific enquiry, the degree of as well as the sources causing variation between them remains incomplet...

    Authors: Michael Nagler, Lucas M Bachmann, Lorenzo Alberio, Anne Angelillo-Scherrer, Lars M Asmis, Wolfgang Korte, Adriana Mendez, Guido Reber, Hans Stricker, Dimitrios A Tsakiris and Walter A Wuillemin
    Citation: Thrombosis Journal 2013 11:6
  29. Giant left atrium is a condition characterized by huge enlargement of the left atrium with a diameter exceeding 65mm. It is most commonly associated with long standing rheumatic mitral valve disease. We presen...

    Authors: Ahmad K Darwazah and Hamdy El Sayed
    Citation: Thrombosis Journal 2013 11:5
  30. Deep Vein Thrombosis (DVT) is an important cause of morbidity and is the first cause of maternal death after delivery in Western Nations. The risk of venous thromboembolism is present throughout the pregnancy ...

    Authors: Leslie Fiengo, Federico Bucci, Gregorio Patrizi, Domenico Giannotti and Adriano Redler
    Citation: Thrombosis Journal 2013 11:4
  31. Early treatment of disseminated intravascular coagulation (DIC) can be associated with improved patient outcomes. The Japanese Ministry of Health and Welfare (JMHW) and the International Society on Thrombosis ...

    Authors: Takahiro Kato, Takamasa Sakai, Miki Kato, Mao Hagihara, Takaaki Hasegawa, Katsuhiko Matsuura and Takashi Nakagawa
    Citation: Thrombosis Journal 2013 11:3
  32. Previous animal studies by us and others have indicated that catheter-administered plasmin or its des-kringle derivatives may be more appropriate alternatives to plasminogen activators for treating thrombolyti...

    Authors: Xiaotao Lin, Yan Wang, Yanwen Zhang, Bing Huang, James J Lin, Scott J Hallock, Hong Yu, Hongwei Shao, Jing Yan, Bo Huang, Xuejun C Zhang, Wei Cao, Xueming Xu and Xinli Lin
    Citation: Thrombosis Journal 2013 11:2
  33. The aim of the present study was to compare circulating levels of selected prothrombotic markers in patients suffering acute myocardial infarction (AMI) with and without left ventricular (LV) thrombus.

    Authors: Svein Solheim, Ingebjørg Seljeflot, Ketil Lunde, Vibeke Bratseth, Svend Aakhus, Kolbjørn Forfang and Harald Arnesen
    Citation: Thrombosis Journal 2013 11:1
  34. Effective treatment of venous thromboembolism (VTE) strikes a balance between prevention of recurrence and bleeding complications. The current standard of care is heparin followed by a vitamin K antagonist suc...

    Authors: Bastian Hass, Jayne Pooley, Adrian E Harrington, Andreas Clemens and Martin Feuring
    Citation: Thrombosis Journal 2012 10:24
  35. Low Frequency Vibro-Percussion (LFVP) assists clearance of thrombi in catheter systems and when applied to the heart and timed to diastole is known to enhance coronary flow. However LFVP on a clotted coronary ...

    Authors: Andrew Hoffmann and Harjit Gill
    Citation: Thrombosis Journal 2012 10:23
  36. Dual antiplatelet treatment with aspirin and clopidogrel is the antithrombotic treatment recommended after an acute coronary syndrome and/or coronary artery stenting. The evidence for optimal antiplatelet ther...

    Authors: Mila Menozzi, Andrea Rubboli, Antonio Manari, Rossana De Palma and Roberto Grilli
    Citation: Thrombosis Journal 2012 10:22
  37. Hump-nosed pit viper (Genus Hypnale) is a medically important venomous snake in Sri Lanka and Southwestern India which causes significant morbidity and mortality. Envenoming of this snake results in hemostasti...

    Authors: Vijayabala jeevagan, Thashi Chang and Christeine Ariaranee Gnanathasan
    Citation: Thrombosis Journal 2012 10:21
  38. Venous thromboembolism (VTE) is a leading cause of hospital-related deaths worldwide. However, the proportion of patients at risk of VTE who receive appropriate prophylaxis in Egypt is unknown. The ENDORSE stu...

    Authors: Hadi A Goubran, Sherif Sholkamy, Alaa El-Haddad, Alaa Mahmoud, Mounir A Rizkallah and George Sobhy
    Citation: Thrombosis Journal 2012 10:20

Official journal of

  • Thrombosis Journal is the official journal of the Asian-Pacific Society on Thrombosis and Hemostasis.

Annual Journal Metrics

  • 2022 Citation Impact
    3.1 - 2-year Impact Factor
    3.8 - 5-year Impact Factor
    1.011 - SNIP (Source Normalized Impact per Paper)
    0.699 - SJR (SCImago Journal Rank)

    2023 Speed
    10 days submission to first editorial decision for all manuscripts (Median)
    107 days submission to accept (Median)

    2023 Usage 
    708,004 downloads
    943 Altmetric mentions